



PCR 2015

**University of Louisville
Department of Medicine**

**Donald Miller, M.D., Ph.D.
Professor
Hematology/Oncology**

CURRICULUM VITAE

Donald M. Miller, M.D., Ph.D.
James Graham Brown Cancer Center
529 S. Jackson St.
Louisville, KY 40202
502-562-4790
502-562-4368 fax
donaldmi@ulh.org

EDUCATION

1963-1967 B.S. in Chemistry and Biology (magna cum laude)
Florida State University
Tallahassee, FL

1967-1973 M.D., Ph.D. (Biochemistry)
Duke University
Durham, N.C.

1973-1975 Residency, Internal Medicine
Peter Bent Brigham Hospital
Harvard University
Boston, MA

1975-1978 Fellowship, Clinical Associate
NHLBI, NIH
Bethesda, MD

1978-1979 Senior Staff Associate
NCI, NIH
Bethesda, MD

ACADEMIC APPOINTMENTS

1974-1975 Clinical Fellow in Medicine
Harvard University
Boston, Massachusetts

1979-1984 Assistant Professor
Department of Internal Medicine
University of Michigan
Ann Arbor, MI

1984-1988 Associate Professor
Department of Internal Medicine
University of Alabama at Birmingham
Birmingham, AL

1984-1990 Director, Hematology Oncology
Birmingham VAMC

Birmingham, AL

1988-1999 Professor
Department of Internal Medicine
University of Alabama at Birmingham
Birmingham, AL

1990-1998 Director, Division of Hematology Oncology
Department of Medicine
University of Alabama at Birmingham
Birmingham, AL

1995-1999 Deputy Director, Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, AL

1999-present Professor
Department of Medicine
University of Louisville School of Medicine
Louisville, KY

1999-present Director, James Graham Brown Cancer Center
University of Louisville
Louisville, KY

1999-Present Associate Vice President for Health Affairs
University of Louisville School of Medicine
Louisville, KY

1999-Present Director, Division of Medical Oncology
Department of Medicine
University of Louisville
Louisville, KY

2000-2001 Interim Chair, Department of Obstetrics and Gynecology
University of Louisville
Louisville, KY

OTHER POSITIONS AND EMPLOYMENT

1984-1999 Director, Bolden Human Molecular Biology Laboratory
Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, AL

1997-1998 Director, Medical Scientist Training Program
University of Alabama at Birmingham
Birmingham, AL

1999-2002 Board of Directors, University Medical Associates,

-President, 1995-1996

HONORS AND AWARDS

1966	Phi Beta Kappa
1966-1967	National Science Foundation Fellowship
1967-1973	Medical Scientist Training Program, Duke University Medical School
1968-1972	American Cancer Society Predoctoral Fellowship
1982-1987	Scholar, Leukemia Society of America
1985	Southern Society of Clinical Investigation
1986-1991	Clinical Investigator, VA Career Development Program
1988-1992	Chancellor, Southern Society of Clinical Investigation
1992	Fellow, Royal Society of Medicine, London
1994	Howard and Martha Holley Research Prize, American College of Rheumatology
1992-1995	Secretary Treasurer, Southern Society of Clinical Investigation
1995	President, Southern Society of Clinical Investigation
1996	Elected to Association of American Physicians
1998-present	<i>Best Doctors in America</i>
1999-present	James Graham Brown Professor of Oncology, University of Louisville
2001	Recipient, Founders Medal, Southern Society of Clinical Investigation
2002	Recipient, Thad Kopple Award, Leukemia Society of America
2003	Recipient, Excaliber Award, American Cancer Society
2004	Recipient, Kentucky HERO Award, Louisville Science Museum
2003	Recipient, The Mint Jubilee Lifetime Achievement Award
2005	Recipient, University Distinguished Medal of Scholarly Accomplishment, University of Louisville
2005	Alumni Member, AOA, Duke University School of Medicine
2006	Named Partner in Health Care by Business First Magazine
2010	Recipient, Distinguished Faculty Award for Service in the community, commonwealth and region, University of Louisville

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

University Assignments:

University of Michigan:

1983-1984	M.D./Ph.D. Program Oversight Committee
1981-1984	Hematology Oncology Fellowship Committee

University of Alabama at Birmingham:

1986-1991	Member, Fellowship Evaluation Committee, Hematology/Oncology Division\
1985-1990	Research Committee, Department of Medicine
1985-1991	Research and Development Committee, Birmingham VA Medical Center
1986-1999	Member of Hematology, Hypertension, Virology, Gynecology, Human Genetics, and Surgical Oncology Training Programs
1987-1992	Chairman, Budget Subcommittee, VA Research Office, Birmingham VA Medical Center
1987-1999	Steering Committee, M.D.-Ph.D Program, University of Alabama at Birmingham.

1988-1992	Chairman, Scientific Advisory Board, Clinical Research Center.
1988-1994	Member, Tenure and Promotions Committee, Internal Medicine.
1988-1991	Member, Pastoral Care Advisory Committee, University of Alabama at Birmingham.
1988-1990	Member, Hypertension Specialized Center Of Research, University of Alabama at Birmingham.
1989-1994	Member, Steering Committee, Hypertension Training Program, University of Alabama at Birmingham.
1989-1990	Member, Committee on Basic Science Departments and Graduate Biomedical Education
1989-1993	Member, Research and Education Committee, Hematology Oncology Division, University of Alabama at Birmingham
1990-1992	Steering Committee, Patient Care 2000, Patient Based Medical Care Project
1990-1997	Faculty Practice Committee, Department of Internal Medicine, UAB
1990-1997	Clinical Director, Hematology Oncology Clinic, The Kirklin Clinic, University of Alabama at Birmingham
1990-1995	Associate Director for Translational Research, Comprehensive Cancer Center, University of Alabama at Birmingham
1990-1999	Executive Committee, Comprehensive Cancer Center, University of Alabama at Birmingham
1992-1995	Faculty Council, University of Alabama at Birmingham Medical School
1992-1999	Co-Director, Molecular Genetics Program, Comprehensive Cancer Center, University of Alabama at Birmingham
1992-1997	Director, Clinical Investigator Training Program, University of Alabama at Birmingham
1992-1997	Member, Executive Practice Committee, The Kirklin Clinic, UAB
1993-1997	Member, Quality Improvement Committee, University Hospital, UAB
1993-1996	University-wide committee on Policies and Procedures
1993-1994	University-wide committee on Mentoring
1994-1995	Genetics Center Planning Committee
1994-1995	Chairman, Institutional Gene Therapy Planning Committee
1994-1999	Member, Advisory Committee of Transgenic Animal Facility, UAB
1994-1995	Member, Advisory Committee, Nurse Practitioner Program, UAB
1994-1995	Member, Search Committee for Chairman of Rehabilitation Medicine
1994-1996	Member, Medical Center Research Advisory Committee
1994-1996	Member, Executive Council of Medical Care Program Review Committee
1994-1995	Member, Chairman's Advisory Committee, Department of Medicine
1995-1997	Member, Chairman's Committee on Education, Department of Medicine
1995-1998	Chairman, Search Committee for Chairman, Department of Radiation Therapy
1995-1998	Member, Credentials Committee, University Hospital
1996-1997	Cochairman, Search Committee for Dean, School of Medicine

University of Louisville:

2000	Member, Search Committee for Chair, Department of Biochemistry & Molecular Biology
2006	Member, Search Committee for Chair, Department of Surgery
2006	Member, Search Committee for Executive Vice President for Health Affairs

2007	Chair, Search Committee for Executive Vice President for Research
2008	Chair, Search Committee for Chair, Department of Medicine
2010	Member, Search Committee for Executive Vice President for Research
2010	Member, Search for Executive Vice President for Health Affairs
2011-present	Member, Medical Advisory Council, Melanoma Know More

Nonuniversity Assignments:

1979-1984	Scientific Advisory Board, Children's Leukemia Foundation of Michigan
1980-1984	Advisory Board, Hospice of Michigan

Veterans' Administration:

1985-1988	National Program Specialist in Oncology, VA Research Administration
1985-1988	Member, Oncology Merit Review Board, VA Research Administration
1985-1994	Associate Editor, American Journal of Medical Sciences
1986-1991	Clinical Investigator, VA Research Career Development Program
1988-1990	Member, District Planning Board, Veterans Administration, Medical District 10
1988-1990	Member, Technical Advisory Group for Oncology, Veterans Administration, Medical District 10
1993-1996	Member, Oncology Merit Review Board, Veterans Administration Research Program
1996	Member, National VA Research Priority Committee
1997	Member, Hematology Merit Review Board, Veterans Administration Research Program

National Institutes of Health:

1986-1988	Hematology II Study Section, NIH, Ad Hoc Member
1988-1992	Hematology II Study Section, NIH
1994	Hematology II Study Section, NIH, Ad Hoc Member
1997-2001	Member, Hematology II Study Section, National Institutes of Health
2000-2002	Chair, Hematology II Study Section, NIH
2006-2008	NCI Training Program Review Committee
2008-Present	NIGMS COBRE Review Committee

American Society of Hematology:

1996	Member, Program Committee, American Society of Hematology (Chairman of Molecular Oncology Section)
------	--

American Cancer Society:

1990-1991	Member, Nucleic Acids Review Group, American Cancer Society
-----------	---

American Federation of Clinical Research:

1990	Chairman, Oncology Program Committee, AFCR National Meeting
1991	Member, Oncology Program Committee, AFCR National Meeting

American Association of Cancer Research:

1992 Member, State Legislative Committee, American Association of Cancer Research
 1992-1993 Member, National Program Committee, American Association of Cancer Research
 1993-1995 Member, Membership Committee, American Association of Cancer Research

Institute of Medicine:

1993 Consultant, Institute of Medicine Committee to advise Army on Breast Cancer Initiative

Cancer Center Scientific Advisory Boards:

1994-Present Member, External Advisory Boards, University of Indiana Cancer Center, West Virginia University Cancer Center, Southern Illinois University, and Medical College of Virginia Cancer Center, University of Miami Cancer Center.

Pharmaceutical Advisory Boards:

1998-Present Member Advisory Boards for Genentech, Dupont, Smith Kline Beecham, Pfizer

EDUCATIONAL ACTIVITIES

Didactic Teaching – I give one lecture per year in the Cancer Biology course

Laboratory Teaching – I have, on average, one to three students or postdoctoral fellows in my laboratory. That teaching is primarily laboratory mentoring.

Teaching Program Administration – I have been Director of the M.D., Ph.D. program since 2002. In that role, I am responsible for the recruitment and retention of three to four M.D., Ph.D. students each year. The program has been quite successful and the graduates have gone on to very strong programs.

CLINICAL ACTIVITIES

1999-Present Medical Director, Brown Cancer Center
 - I direct the clinical programs of the Brown Cancer Center and have been responsible for the development of the Multidisciplinary Cancer Clinics at the Center.

1979-Present Attending Physician – Medical Oncology Service
 - I attend for one month per year (on average) on the inpatient Medical Oncology Service which is comprised of two fellows, one resident and one or more medical students. In general, the average census of the service is from 10 to 17 patients.

1999-Present Member, Melanoma Multidisciplinary Clinic, Brown Cancer Center

- I see patients one day a week in the Melanoma clinic at the Brown Cancer Center. In general, the clinic sees 50 to 6 melanoma patients each week and provides followup care for these patients.

GRANTS AND CONTRACTS:**CURRENT GRANT SUPPORT:**U.S. Public Health Service COBRE Grant

Title: Molecular Targets for Novel Cancer Therapies
 Name of PI: Donald M. Miller, M.D., Ph.D.
 Direct Costs: \$2,000,000/year
 % Effort: 15%
 Period of Support: 9/03-9/13

Helmsley Trust Foundation

Title: Support for the Owensboro Cancer Research Program
 Role: PI
 Direct Costs: \$8,500,000
 % Effort: N/A
 Period of Support: 2011-2017

PENDING GRANT SUPPORT:U.S. Public Health Service

1U01HL127518-01 (MPI)

Title: The ExCITE Program: Expediting Commercialization, Innovation, Translation, & Entrepreneurship
 Role: Co-PI
 % Effort: 10%
 Period of Support: 2/2015-1/2020

U.S. Public Health Service

1R01CA197274-01

Title: Targeting c-Myc Transcription
 Role: PI
 % Effort: 20%
 Period of Support: 2/2015-1/2020

U.S. Public Health Service

STTR Application with Advanced Cancer Therapeutics

Title: Targeting hTERT Expression in Melanoma
 Role: Co-PI
 % Effort: 10%
 Period of Support: 2/2015-1/2016

Melanoma Research Alliance

Title: Targeting Expression of the Mutated hTERT Promoter

Role: PI
% Effort: 10%
Period of Support: 6/2015-5/2018

DOD Breast Cancer Breakthrough Research Program

Title: Targeting c-Myc and Estrogen Receptor in Breast Cancer
Role: Co-PI (Francine Rezzoug, Ph.D., PI)
% Effort: 5%
Period of Support: 6/2015-5/2018

PAST GRANT SUPPORT:

James Graham Brown Foundation

Title: Development of the Brown Cancer Center
Name of PI: Donald M. Miller
Direct Costs: \$4,000,000/year
% Effort: 40%
Period of Support: 1/2009-12/2013

U.S. Public Health Service

Title: P20 Cancer Center Planning Grant
Name of PI: Donald M. Miller, M.D., Ph.D.
Direct Costs: \$175,000/year (no cost extension)
% Effort: 25%
Period of Support: 9/02-8/08

James Graham Brown Foundation

Development of the Brown Cancer Center (P.I.)
Direct Costs: \$5,000,000/year
Period of Support: 12/01- 11/04

U.S. Public Health Service Grant No. 3RO1 CA42664-14

Modulation of Oncogene Expression in Differentiating Leukemic Cells. (P.I.)
Direct Costs: \$225,000/year
Period of Funding: 9/1/85 - 12/31/2001

U.S. Public Health Service Grant No. 2RO1 CA42664-9

Antiproliferative effects of DHFR and Cyclin D1 Inhibition. (P.I.)
Direct Costs: \$225,000/year
Period of Funding: 9/1/90 - 12/31/2001

U.S. Army Prostate Initiative Grant

Prostate Cancer Growth Inhibitory Oligonucleotides (P.I.)
Direct Costs: \$179,000/year
Period of Support: 1998-2002

U.S. Public Health Service Grant No. 5P30CA13148

UAB Comprehensive Cancer Center Grant (Albert LoBuglio, PI)

Direct Costs: N/A
 Role: Senior Cancer Center Administration, Program Director
 Period of Funding: 1984-1999

VA Merit Review Grant

Regulation of Gene Expression in Regenerating Liver (P.I.)

Direct Costs: \$175,000/year
 Period of Support: 1985-1999

Appollon, Inc.

Grant to Develop Triplex Therapeutics (P.I.)

Direct Costs: \$250,000
 Period of Support: 1998

U.S. Public Health Service Grant

Modulation of Immune Response in Cancer. (Ray Hiramoto, P.I.; Donald Miller, co-P.I.)

Direct Costs: \$200,000/year
 Period of Funding: 9/1/85 - 12/31/1991

U.S. Army Breast Cancer Initiative Grant

Triplex Directed Therapy of Breast Cancer (P.I.)

Direct Costs: \$250,000/year
 Period of Support: 1982-1987

Melanoma Research Foundation

Transcriptional Inhibition in Melanoma (P.I.)

Direct Costs: \$200,000/year
 Period of Support: 1991-1994

VA RAG Grant

Molecular Regulation of Liver Regeneration (P.I.)

Direct Costs: \$50,000/year
 Period of Support: 1984-1985

Elsa U. Pardee Foundation Grant

Molecular Regulation of Liver Regeneration (P.I.)

Direct Costs: \$35,000/year
 Period of Support: 1981-1984

Leukemia Society of America Scholar Award

Mithramycin Effects on Leukemic Cells (P.I.)

Direct Costs: \$25,000/year

Period of Support: 1981-1986

Children's Leukemia Fund of Michigan
Inhibition of Gene Expression in Leukemic Cells (P.I.)
Direct Costs: \$20,000/year
Period of Support 1979-1983

Dr. Miller has also been P.I. on more than 30 clinical trials with funding exceeding \$3 million.

PATENTS

ISSUED

US Patent 8,586,717, Method for the Diagnosis and Prognosis of Malignant Diseases. Issued November 19, 2013.

U.S. Patent 8,410,070, Compositions and methods for treating cancer, inhibiting proliferation, and inducing cell death. Issued April 2, 2013.

US Patent U.S.8,029,784, Method for the Diagnosis and Prognosis of Malignant Diseases. Issued October 4, 2011.

US Patent 7,960,540, Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin . Issued June 14, 2011

U.S. Patent 7,541,150 Methods for the diagnosis of cancer by determining the neoplastic status of a cell by probing the cell plasma membrane for the presence of nucleolin are provided, as are kits to carry out such tests. Issued June 2, 2009.

U.S. Patent 7,357,928 Methods for the treatment of tumors and cancer by exploiting the surface expression of the usually nuclear-localized protein, nucleolin. Issued April 15, 2008.

U.S. Patent 7,314,926 Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin. Issued January 1, 2008.

Pending

U.S. Provisional Patent Application: 61/900,570, Family of G-rich Genomic Sequences Interact Specifically with the Pu27 Silencer Element of the c-Myc Promoter. Filed: November 6, 2013.

EDITORIAL WORK:

1989-1995	Associate Editor, American Journal of Medical Sciences
1995-Present	Editorial Board, American Journal of Medical Sciences
2008-Present	Editorial Board, Genetic Testing and Molecular Biomarkers
2010-Present	Editorial Board, Translational Medicine
2012-Present	Editorial Board, Ovarian Cancer Research

ABSTRACTS AND PRESENTATIONS

-More than 200 abstracts, details provided on request.

ORAL PRESENTATIONS

-Over the past forty years I have averaged three to six presentations per year.

PUBLICATIONS:

1. Pine, L., Taylor, T., Miller, D., Bradley, G., Wetmore, H.R.: The comparison of good and bad lots of trypsin used in the production of primary monkey kidney cells. *Cytobios* 1:197-202, 1969
2. Pine, L., Bradley, C., **Miller, D.**: Collagenolytic activity and the comparison of good and bad lots of commercial trypsin in the preparation of primary monkey kidney cells. *Cytobios* 4:347-356, 1969.
3. Specificity of acetylation of lysine-rich and slightly lysine-rich histones. Ph.D. Thesis, **Donald M. Miller**, Duke University, Durham, North Carolina. 1972.
4. Marzluff, W.F., Sanders, L.A., **Miller, D.M.**, McCarty, K.S.: Two chemically and metabolically distinct forms of calf thymus F3 histone. *J. Biol. Chem.* 247:2026, 1972.
5. Marzluff, W.F., **Miller, D.M.**, McCarty, K.S.: The occurrence of E-N-acetyl-lysine in calf thymus histone F2b. *Arch. Biochem. Biophys.* 152:472, 1972.
6. Miller, D., Laszlo, J., Lyons, G., Kelso, H., **Miller, D.M.**, McCarty, K.S.: Reduction of blood asparagine by hemodialysis. *Cancer* 29:1347, 1972.
7. **Miller, D.M.**, Williams, R., McCarty, S.: Histone acetylation on isolated chromatin. *Biochem. Biophys. Acta.* 234:437, 1973.
8. **Miller, D.M.**, Axelrod, D., Croissant, R., Nienhuis, A.W.: Structure of the globin gene in differentiating erythroid cells. *The Red Cell* pp. 17-30, 1978, Alan R. Liss, Inc., New York, New York.
9. **Miller, D.M.**, Turner, P., Nienhuis, A.W., Axelrod, D.E., Gopalakrishanan, T.K.: Active conformation of the globin genes in uninduced and induced mouse erythroleukemia cells. *Cell* 14:511-522, 1978.
10. Nienhuis, A.W., Axelrod, D., Barker, J.F., Benz, E.J., Croissant, R., **Miller, D.M.**, Young, N.: Regulation of the individual genes, differentiation of normal and neoplastic hematopoietic cells. pp. 295-310, 1978, Cold Spring Harbor, Laboratory.
11. Nienhuis, A.W., Barker, J.E., Benz, E.J., Croissant, R.D., Kantor, J.A., Kretchmer, P., **Miller, D.M.**, Young, N.: Regulation of hemoglobin switching in sheep: *Cell. Molec. Aspects. ICN-UCLA Symposium*, 1978.
12. Nienhuis, A.W., Benz, E.J., Jr., **Miller, D.M.**, Steggle, A., and Young, N.S.: Chromatin structure and transcription of the globin genes. In *Current Concepts of the Structure and Function of DNA, Chromatin, and Chromosomes.* (Eds.) A.S. Dion, Miami Symposia Specialists, 1979, pp.211-213.
13. **Miller, D.M.**, Winslow, R.W., Klein, H., Brown, F.: Effects of exchange transfusion on oxygen delivery in sickle cell anemia. *Blood* 56:1127-1131, 1980.

14. Klein, H.G., Brown, F., **Miller, D.M.**, Winslow, R.W.: Use of a cell separator for exchange transfusion in sickle cell anemia. *Transfusion* 20:93-98, 1980.
15. **Miller, D.M.**, Yang, A.: Leukocyte alkaline phosphatase: Another organ-specific alkaline phosphatase. *Am. J. Hematol.* 15:171-180, 1983.
16. **Miller, D.M.**, Yang, A.: LAP isozymes in normal and diseased states. *Brit. J. Hematol.* 57:145-154, 1984.
17. Yang, A., **Miller, D.M.**: Preparation of functional RNA from granulocytes. *J. Lab. Clin. Med.* 105:94-98, 1985.
18. **Miller, D.M.**, Yang, A.: Leukocyte alkaline phosphatase: Purification from normal and leukemic leukocytes. *Am. J. Hematol.* 18:159-169, 1985.
19. Polansky, D., Yang, A., Brader, K., **Miller, D.M.**: Control of lysozyme gene expression in differentiating HL-60 cells. *Brit. J. Hematol.* 60:7-17, 1985.
20. Lynch, J.P., Flint, A., **Miller, D.M.**, Joseph, C.: Noncaseating pulmonary granulomas associated with small cell carcinoma of the lung. *Am. J. Med.* 78:691-696, 1985.
21. Koller, C.A., Campbell, V.W., Yang, A., Mulhern, A., **Miller, D.M.**: Expression of c-myc and c-abl proto-oncogenes during in vivo differentiation of blast phase chronic granulocytic leukemia. *J. Clin. Invest.* 76:365-369, 1985.
22. Koller, C., **Miller, D.**: Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. *NEJM* 315:1433-1438, 1986.
23. Sanchez, J., Baker, V., **Miller, D.M.**: Basic mechanisms of metastasis. *Am. J. Med. Sci.* 292:376-385, 1986.
24. Monk, M.R., Sanchez, J.D., Phelps, C., **Miller, D.M.**: Myocardial ischemia with fluorouracil and floxuridine therapy. *Clin. Pharm.* 6:659-661, 1987.
25. **Miller, D.M.**, Polanski, D.A., Thomas, S.D., Ray, R., Campbell, V.W., Sanchez, J., Koller, C.A.: Mithramycin selectively inhibits transcription of G-C containing DNA. *Am. J. Med. Sci.* 294(5):388-394, 1987.
26. Baker, V.V., Shingleton, H.M., Hatch, K.D., **Miller, D.M.**: Selective Inhibition of c-myc expression by the ribonucleic acid synthesis inhibitor mithramycin. *Am. J. Obs. and Gyn.* 158(4):762-767, 1988.
27. Gualtieri, R.J., Castleberry, R.P., Gibbons, J., **Miller, D.M.**, Berkow, R.L., Parmley, R.T., Banks, J.: Cell culture studies and oncogene expression in juvenile chronic myelogenous leukemia. *Exp. Hematol.* 16:613-619, 1988.
28. Saleh, M.N., **Miller, D.M.**, Peterson, L., Russell C.D., Unger, M.W., Urist, M.M., Wheeler, R.H., LoBuglio, A.F. Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma. *J. Clin. Oncol.* 6:1059-1065, 1988.

29. **Miller, D.M.**, Sanchez, J.D., Ray, R., Snyder, R.C., Blume, S., Shrestha, K., Bailey, A., Bounelis, P., Thomas, S., Pezzementi, M., Rigsby, D., Hunter, D., Koller, C.A.: Selective modulation of gene expression, a new approach to drug resistant tumors. Accomplishments in Cancer Research, 3:119-135, 1989.
30. Ray, R., Snyder, R., Thomas, S., Koller, C.A., **Miller, D.M.**: Mithramycin blocks protein binding and function of the SV40 early promoter. *J. Clin. Invest.* 83:2003-2007, 1989.
31. Ray, R., Thomas, S., **Miller, D.M.**: Expression of a transfected c-myc under the control of its own promoter. *Oncogene* 4:593-600, 1989.
32. Baker, V., Thomas, S., Sanchez, J., Wheeler, R., **Miller, D.M.**: Dissociation of cellular proliferation and c-myc expression by yellowroot tea, a Southern folk medicine. *Am. J. Med. Sci.* 298:283-288, 1989.
33. Roesel, J., Rigsby, D., Bailey, A., Alvarez, R., Sanchez, J.D., Campbell, V., **Miller, D.M.**: C-myc expression is stimulated by a circulating non-organ specific factor in regenerating liver. *Oncogene Res.* 5,129-36, 1989.
34. Alvarez, R., Bailey, A., Grizzle, W., **Miller, D.M.**: Distinction between compensatory ovarian hypertrophy and liver regeneration. *Am. J. Obst. and Gyn.* 161:1653-1657, 1989.
35. Borst, M., **Miller, D.M.**: DNA Isolation and Southern Analysis in Clinical Medicine. *Amer. J. Med. Sci.*, 299:356-360,1990.
36. **Miller, D.M.**, Blume, S., Borst M., Gee, J., Polansky, D., Ray, R., Snyder, R.C., Shrestha, K., Thomas, S., Tran-Patterson, R.: Malignant Transformation and Modern Medicine. *Amer. J. Med. Sci.* 300:59-69, 1990.
37. Bailey, A., Rigsby, D., Roesel, J., Alvarez, R., Sanchez, J.D., **Miller, D.M.**: C-myc and c-Ha-ras expression in response to a regenerative stimulus is not organ specific. *Oncogene Res.* 5:287-294,1990.
38. Ray, R., Thomas, S., **Miller, D.M.**: The G-C specific DNA binding drug, mithramycin, selectively inhibits the promoter function of a transfected c-myc gene. *Am. J. Med. Sci.*, 299:203-208, 1990.
39. Borst, M.P., Baker, V.V., Hatch, K.D., Shingleton, H.M., **Miller, D.M.**; Oncogene abnormalities in endometrial carcinoma. *Gyn. Onc.* 38:364-366, 1990.
40. Baker, V.V., Borst M.P., Dixon, D., Hatch, K.D., Shingleton, H.M., **Miller, D.M.**: c-myc amplification in ovarian cancer. *Gyn. Onc.* 38:340-342, 1990.
41. Huang, D-H, Sakai, T.T., **Miller, D.M.**, Krishna, N.R., Proton 2D-NMR and spectrofluorometric Characterization of Mithramycin, a DNA Binding Drug. *J. Antibiotics*, 43:1543-1552, 1990.
42. Sawamura, M., Everson, M.P., Shrestha, K., Ghanta, V.K., **Miller, D.M.**, Hiramoto, R.N.: Characterization of 5B12.1, a monoclonal antibody specific for IL-6. *Growth Factors* 3:181-90, 1990.

43. Snyder, R.C., Ray, R., Sanchez, J.D., Blume, S., Koller, C.A., **Miller, D.M.**: Mithramycin selectively inhibits c-myc transcription by blocking protein binding to its promoter region. *Biochemistry*, 30:4290-4297,1991.
44. Rodu, B., Christian, C., Snyder, R., Ray, R., **Miller, D.M.**: Novel use of polymerase chain reaction to detect and subtype human papilloma virus sequences in oral lesions. *Biotechniques*, 10:632-635, 1991.
45. Ray, R., **Miller, D.M.**: Cloning and characterization of a c-myc regulatory protein. *Mol. Cell. Biol.*, 11:2154-2161, 1991.
46. Wolfe, G.T., **Miller, D.M.** and Veterans Affairs Laryngeal Cancer Study Group: Induction Chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. *N. Engl. J. Med.* 324:1685-1690, 1991.
47. Bailey, A., Sanchez, J.D., Shrestha, K., Tran-Patterson, R., Saliba, D., **Miller, D.M.**: Induced Protooncogene Expression is Associated with a Marked Increase in Susceptibility to Carcinogenesis. *Chemically Induced Cell Proliferation, Prog. Clin. Biol. Res.* 369:105-114, 1991.
48. Blume, S., Hunter, D., Ray, R., Snyder, R., Thomas, S., Shrestha, K., **Miller, D.M.**: Selective inhibition of DHFR gene expression reverses methotrexate resistance. *J. Clin. Invest.*, 88:1613-1621, 1991.
50. Hiramoto, RN., Hiramoto, NS., Rish, ME., Soong, SJ., **Miller, DM.**, Ghanta, VK.:Role of immune cells in the Pavlovian conditioning of specific resistance to cancer. *Int. J. Neurosci.* 59:101-17, 1991.
51. **Miller, D.M.**: Hematology, in Cooper, J.A.D., and Pappas, P.G.: Cecil Review of General Internal Medicine, W.B. Saunders Co., Philadelphia, PA.; 102-121, 1992.
52. Snyder, R.S., **Miller, D.M.**: Transcriptional and Posttranscriptional Regulation of c-myc Expression. *Crit. Rev. Oncogen.*, 3:283-291,1992.
53. Gee, J., Ray, R., Snyder, R., Blume, S., **Miller, D.M.**: Triplex formation prevents Sp1 binding to its cognate DNA binding site. *J. Biol. Chem.*, 267, 11163-11167, 1992.
54. Blume, S.W., Gee, J., Shrestha, K., **Miller, D.M.**: Triple helix formation by purine-rich oligonucleotides targeted the human dihydrofolate reductase promoter. *Nucleic Acids Res.* 20:1777-1784, 1992.
55. **Miller, D.M.**: Future Therapy Against Cancer. *Oncology Update* 1:17-18, 1992
56. Tran-Patterson, R., Davin, D., Krauss, R., Rado, T., **Miller, D.M.**: Stimulation of CFTR gene expression during liver regeneration. *Am. J. Physiol.* 263:C55-C60, 1992.
57. Saleh, M.N., Khazaeli, M.B., Wheeler, R.H., Tiepu Liu, Urist M., **Miller, D.M.**, Lawson, S., Dixon, P., Russell, C.H., LoBuglio, A.F.: A Phase I trial of the Murine Monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. *Cancer Res.* 52:1-6, 1992.

58. Ghanta, V.K., Hiramoto, N.S., Soong, S.J., **Miller, D.M.**, Hiramoto, R.N.: A multiple modality approach combining the effect of conditioning with adoptive chemoimmunotherapy. *Intern. J. Neurosci.* 71:251-256, 1993.
59. Helm, W., Shrestha, K., **Miller, D.M.**: Inhibition of ovarian carcinoma cell proliferation by triplex forming oligonucleotides and their acridine conjugates. *Gyn. Onc.*, 49:339-343, 1993.
60. Ebbinghaus, SW, Gee JE, Rodu B, Mayfield CA, Sanders G, and **Miller DM**: Triplex formation inhibits HER-2/neu transcription in vitro. *J. Clin. Invest.* 92:2433-2439, 1993.
61. Gee, J., **Miller, D.M.**: Structure and Application of Intermolecular DNA Triplex; *Am. J. Med. Sci.*, 304:366-372, 1993.
62. E. Gee, Ebbinghaus, C.Mayfield, G.Sanders, B.Shrestha, B.Rodu, K.Rabenau, **D.M. Miller**: Potential therapeutic usefulness of intermolecular triplex DNA in Cancer Therapy in the Twenty-First Century; *Molecular and Immunologic Approaches*; Huber, B. and Carr, B.I., Ed.; Futura; Mount Kisco, N.Y. pp. 163-177, 1994.
63. Campbell, V.W., Roesel, J., Rigsby, D., Sanchez, J.D., Ray, R., Shrestha, K., Nalluswami, K., Stone, T., **Miller, D.M.**: The B-C Specific DNA Binding Drug, Mithramycin, Selectively Inhibits Transcription of the C-MYC and C-HA-RAS Genes in Regenerating Liver *Am. J. Med. Sci.*, 307:167-172, 1994.
54. Meluch, A., **Miller, D.M.**: Genetics of Hematopoietic/Lymphopoietic Malignancies in Hematology: A Problem Oriented Approach, S.Gross and S.Roath, Ed., Williams and Wilkens Press, Baltimore, 1994.
65. Urist, MM, **Miller, DM**, Maddox, WA: Malignant Melanoma in Murphey, G.P., Lawrence W, Lenhard RE, (Editors). American Cancer Society Textbook of Clinical Oncology. Second Edition, American Cancer Society, Atlanta, 304-310, 1995.
66. Mayfield, C., Squibb, M., **Miller, D.M.**: Inhibition of Nuclear Protein Binding to the Human Ki-ras Promoter by Triplex-Forming Oligonucleotides. *Biochemistry*, 33:3358-3363, 1994.
67. Mayfield, C. and **Miller, D.M.**: Effect of abasic linker substitution on triplex formation, Sp1 binding, and specificity in an oligonucleotide targeted to the human Ha-ras promoter. *Nuc. Acids Res.* 22:1909-1916, 1994.
68. C. Mayfield, S. Ebbinghaus, J. Gee, D. Jones, B. Rodu, M. Squibb and **D. Miller**: Triplex formation by the human Ha-ras Promoter Inhibits Sp1 Binding and in Vitro Transcription. *J. Biol. Chem.*, 27:18232-1823, 1994.
69. Chen, S.J., Chen, Y.F., **Miller, D.M.**, Oparil, S.: Mithramycin Inhibits Myointimal Proliferation after Balloon Injury of the Rat Carotid Artery In Vivo. *Circulation*, 90:2468-2473, 1994.
70. Ray R, Shrestha K., **Miller, D.M.**: Isolation and characterization of a cDNA clone showing c-myc binding activity. *Int. J. Cancer* 5:111-115, 1994.
71. Jones, D.E., Tran-Patterson R, Davin D, **Miller DM**: Epidermal growth factor secreted from the salivary gland is necessary for liver regeneration. *Amer. J. Phys.*, 268:G872-G878, 1995.

72. Chaudhary, D., **Miller, D.M.**: The c-myc promoter binding protein MBP-1 and TBP bind simultaneously in the minor groove of the c-myc P2 promoter. *Biochemistry*, 34:3438-3445, 1995.
73. Jones, D.E., Cuí, D.M., **Miller, D.M.**: Expression of beta-galactosidase under the control of the human c-myc promoter in transgenic mice is inhibited by mithramycin. *Oncogene*, 10:2323-2330, 1995.
74. Reddoch, J., **Miller, D.M.**: Inhibition of nuclear protein binding to two sites in the murine c-myc promoter by intermolecular triplex formation. *Biochemistry*, 34:7659-7667, 1995.
75. Kim, H., Mayfield, C., Sanders, G., Ebbinghaus, S., Vigneswaran, N., Miller, R., **Miller, D.M.**: Triplex formation by the Mc1A1 binding site of the human c-myc promoter. *Biochemistry*, 34:8165-8171, 1995.
76. **Miller, D.M.**: The Future of Oncology in Cecil, Textbook of Medicine, Edition 14, In Press, 1995.
77. Vigneswaran, N., D., Rodu, B, **Miller, D.M.**: Influence of GC and AT-specific DNA binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter. *Biochemistry*, 35:1106-1114, 1996.
78. Ebbinghaus, S.W., Vineswaran, N., Miller, C.R., Chee-Awai, R.A., Mayfield, C.A., Curiel, D.T., **Miller, D.M.**: Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. *Gene Therapy*, 3:287-297, 1996.
79. Pittman, JA Jr., **Miller, D.M.**: The Southern Society for Clinical Investigation at 50: the end of the beginning. *Am. J. Med. Sci.* 311:248-253, 1996.
80. Blume, SW, Buarcello V, Zacharias W, **Miller DM**: Divalent Transitions Metal Cations Counteract Potassium-induced quaraplex assembly of
81. Blume, S.W., Mayfield C., Sanders, C., Ebbinghaus, S.W., Rodu, B., **Miller, D.M.**: Triplex Forming DNA Binding Compounds as Therapeutic Agents. *Molecular Medicine*, 1998.
82. Kim, H., **Miller, D.M.**: A Novel Triplex Forming Oligonucleotide Targeted to Human Cyclin D1 (bc1-1) Promoter Inhibits Transcription in HeLa Cells. *Biochemistry*, 37:2666-2672.1998.
83. Kim, H., Reddoch, J.F., Mayfield, C., Ebinghaus, S., Vigneswaran, N., Thomas, S., **Miller, D.M.**: Inhibition of Transcription of the Human *c-myc* Proto-oncogene by Intermolecular Triplex. *Biochemistry*, 37:2299-2304, 1998.
84. Ebbinghaus, S.W., Vigneswaran, N., Mayfield, C.M., Curiel, D.T., **Miller, D.M.**: Oligonucleotide Uptake and Delivery in Tissue Culture Cells in Triple Helix Forming Oligonucleotides, Malvy C, and Harel-Bellan A, Eds., Kluwer Academic Publishers, Norwell, MA, 1998.
85. Blume, S.W., Lebowitz, J., Zacharias, W., Cuarcello, V., Mayfield, C.A., Ebbinghaus, S.W., Bates, P.J., Jones, D.E., Trent, J.O., Vigneswaren, N., **Miller, D.M.**: The integral divalent cation within the intermolecular purine* purine-pyrimidine structure: a variable determinant of the potential for and characteristics of the triple helical association. *Nucleic Acids Res.* 27:695-702, 1999.
86. Ebbinghaus, S.W., Vigneswaran, N., Miller, C.R., Chee-Awai, R.A., Mayfield, Curiel, D.T., **Miller, D.M.**: Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes. *Gene Ther.* 3:287-97, 1996.

87. Urist, M.M., **Miller, D.M.**, Heslin, M.: Malignant Melanoma in Murphey, G.P. (Editor). American Cancer Society Textbook of Clinical Oncology. Third Edition, American Cancer Society, Atlanta, 305-312. 1999.
88. Gonzalez, R., Ebbinghaus, S., Henthorne, T., **Miller, D.M.**, Kraft, A.S.: Treatment of Patients with Metastatic Melanoma with Bryostatins-1, a Phase II Study. *Melanoma Research*, 9:599-606, 1999.
89. Bates, P.J., Kahlon, J.B., Thomas, S.D., Trent, J.O., **Miller, D.M.**: Antiproliferative activity in G-rich oligonucleotides correlates with protein binding. *J Biol Chem*. 274:26369-77, 1999.
90. **Miller DM**, Castillos FA: New approaches to screening for cervical cancer in high-risk populations. *J Lab Clin Med*. 135:12-3, 2000.
91. Subramanian A, **Miller DM**: Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. *J Biol Chem*. 275:5958-65, 2000.
92. Vignewaran N., Zhao W., Dassanayake A, Muller S, **Miller DM**, Zacharias W: Variable Expression of Cathepsin B and D Correlates with Highly Invasive and Metastatic Phenotype of Oral Cancer. *Human Pathology* 31:931-937, 2000.
93. Todd, RF 3rd, **Miller DM**, Silverstein RL: Hematology Grants Workshop-2000. *Hematology (Am Soc Hematol Educ Program)*. 2000:424-437.
94. **Miller DM**; Southern Society for Clinical Investigation Founders Medal recipient's address. *Am J Memd Sci*. 2001 Oct;322(4):182-3.
95. Stewart DA, Thomas SD, Mayfield CA, **Miller DM**; Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation. *Nucleic Acids Res*. 2001 29(19):4052-61.
96. Vigneswaran N, Thayaparan J, Knops J, Trent JO, Potaman V, **Miller DM**, Zacharias W; Intra- and intermolecular triplex DNA formation in the murine c-myc proto-oncogene promoter are inhibited by mithramycin. *Biol Chem*. 2001 feb; 382(2):329-42.
97. Todd RF 3rd, **Miller DM**, Silverstein RL: Hematology grants workshop-2001. *Hematology (Am Soc Hematol Educ Program)*. 507-21, 2001.
98. Xu X, Hamhouyia F, Thomas SD, Burke TJ, Girvan AC, McGregor WG, Trent JO, **Miller DM**, Bates, PJ: Inhibition of DNA replication and induction of S phase cell cycle arrest by G-rich oligonucleotides. *J Biol Chem*. 276:43221-30, 2001.
99. Dapic V, Bates PJ, Trent JO, Rodger A, Thomas SD, **Miller DM**: Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. *Biochemistry*. 2002 Mar 19; 41(11):3676-85.
100. Bates PJ, Reddoch JF, Hansakul P, Arrow A, Dale R, **Miller DM**: Biosensor detection of triplex formation by modified oligonucleotides. *Anal Biochem*. 2002 Aug 15; 307(2):235-43.
101. Stewart DA, Xu X, Thomas SD, **Miller DM**: Acridine-modified, clamp-forming antisense oligonucleotides synergize with cisplatin to inhibit c-myc expression and B16-F0 tumor progression. *Nucleic Acids Research*, 2002 Jun 1;30(11):2565-74.

102. Inge TH, Casson LK, Priebe W., Trent JO, Georgeson KE, **Miller DM**, Bates PJ. Importance of Sp1 consensus motifs in the MYCN promoter. *Surgery*. 2002 Aug; 132(2):232-8.
104. **Miller , DM**, Bates PJ and Nabell L: Molecular Biology of Breast Cancer in *Cancer of the Breast*, edited by W.L. Donegan, J.S. Spratt, 5th Edition, Copyright 2002, Elsevier Science, USA, St. Louis, MO.
105. Meng Z, Snyder RC, Shrestha K, **Miller DM**, Emanuel PD, Blume SW. Evidence for differential ribonucleoprotein complex assembly in vitro on the 5'-untranslated region of the human IGF-IR transcript. *Mol Cell Endocrinol*. 2003 Feb 28;2003(1-2):127-40.
106. Kakar SS, Winters SJ, Zacharias W, **Miller DM** and Flynn S: Identification of Distinct Gene Expression Profiles Associated with Treatment of LbetaT2 Cells with Gonadatropin-Releasing Hormone Agonist Using Microarray Analysis, *Gene*, 2003 Apr 10;308:67-77.
107. Mi Y, Thomas SD, Xu X, Casson LK, **Miller DM**, Bates, PJ. Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin. *J Biol Chem*. 2003 Mar 7;278(10):8572-9.
108. **Miller DM**: Adjuvant Treatment of Melanoma in *Clinical Oncology, Practical Aspects*, edited by IM Muse and A Viola, 1st Edition, Copyright 2003, Servicio de Oncologia Clinia, Universidad de la Republica Uruguay, Montevidea, Uruguay.
109. Blume SW, **Miller DM**, Guarcello V, Shrestha K, Meng Z, Snyder RC, Grizzle WE, Ruppert JM, Gartland GL, Stockard CR, Jones DE Jr., Emanuel PD. Inhibition of tumorigenicity by the 5'-untranslated RNA of the human c-myc P0 transcript. *Exp Cell Res*. 2003 Aug 1;288(1):131-42.
110. Laber, DA, Okeke RI, Arce-Lara C, Taft BS, Schonard CL, McMasters KM, Kloecker GH, **Miller, DM**. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. *J Cancer Res Clin Oncol* 132(9):611-6, 2006
111. Sedoris, KC, Thomas, SD, **Miller, DM**. c-myc promoter binding protein regulates the cellular response to an altered glucose concentration. *Biochemistry* 2007 Jul 24;46(29):8659-68.
112. Garbett NC, Mill JJ, Jenson AB, **Miller DM**, Chaires JB. Interrogation of the plasma proteome with differential scanning calorimetry. *Clin Chem*. 2007 Nov;53(11):2012-4.
113. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, Cramer D, Lear SC, McMasters KM, **Miller DM**, Chesney J. Transient T cell depletion causes regression to melanoma metastases. *J Transl Med*. 2008 Mar 11;6(1):12
114. N. Courtenay-Luck, **Miller DM**: AS1411: *Development of an Anticancer Aptamer in Therapeutic Oligonucleotides*, RSC Publishing, Royal Society of Chemistry, London, 2008.
115. Fan, TW, Higashi RM, Bousamra, M, Kloecker, G, **Miller, DM**; Metabolic Profiling Identifies Lung Cancer Responsiveness to Erlotinib. *Exp. Mol. Pathol*, 2009, Aug;87(1):83-6.
116. Desai PC, Jaglal MV, Ghim SJ, **Miller DM**, Farghaly H, Jenson AB; Human papillomavirus in metastatic squamous carcinoma from unknown primaries in the head and neck: a retrospective 7 year study. *Exp. Mol. Pathol*. 2009, Oct;87(2):94-8.

117. Jenson AB, Eaton JW, **Miller DM**; Cancer Research at the James Graham Brown Cancer Center, University of Louisville. *Exp. Mol. Pathol.* 2009 Jun;86(3):139-40.
118. Bates PJ, Laber DA, **Miller DM**, Thomas SD, Trent JO; Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. *Exp. Mol. Pathol.* 2009 Jun; 86 (3):151-164.
119. Lane AN, Fan TW, Higashi RM, Tan J, Bousamra M, **Miller DM**; Prospects for clinical cancer metabolomics using stable isotope tracers. *Exp. Mol. Pathol.* 2009 Jun; 86 (3):165-173.
120. Khan MI, Chesney JA, Laber DA, **Miller DM.** ; Digitalis, a Targeted Therapy for Cancer?, *Am J Med Sci.* 2009 May;337(5):355-9.
121. Jaglal, M, Laber DA, Arnold FW, **Miller DM**, Chesney JA, Kloecker GH.; Obtaining Routine Blood Cultures During Interleukin-2-Containing Therapy Is Unnecessary. *Am J Clin Oncol.* 2009 Aug; 32(4):429-31.
122. Fan, TW, Lane, AN, Higashi, RM, Farag, MA, Gao, H, Bousamra, M, and **Miller, DM**: Altered Regulation of Metabolic Pathways in Human Lung Cancer Discerned by (13)C Stable Isotope-Resolved Metabolomics (SIRM). *Molecular Cancer*, 2009 Jun 26;8:41.
123. Rabinowits G, Bhupalam L, **Miller DM**, Kloecker GH, Laber DA: Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. *Am J Med Sci.* 2010 Feb;339(2):148-51.
24. Sedoris KC, Thomas SC, **Miller DM**: Hypoxia induces differential translation of enolase/MBP-1. *BMC Cancer*, 2010 Apr 22;10:157.
125. Sun D, Zhuang X, Xiang X, Liu Y, Shang S, Liu C., Barnes S, Grizzle W, **Miller D** and Zhang HG: A Novel Nanoparticle Drug Delivery System: The Anti-inflammatory Activity of Curcumin is Enhanced when Encapsulated in Exosomes. *Mol Ther.* 2010 Sep;18(9):1606-14.
126. Lane AN, Fan TW, Bousamra M, Higashi RM, Yan J, **Miller DM.** Stable Isotope-Resolved Metabolomics (SIRM) in Cancer Research with Clinical Application to Non-Small Cell Lung Cancer. *OMICS.* 2011 March;15(3):173-82.
127. Deng Z, Pardi R, Cheadle W, Xiang X, Zhang S, Shah SV, Grizzle W, **Miller D**, Mountz J, Zhang HG. Plant homologue constitutive photomorphogenesis 9 (COP9) signalosome subunit CSN5 regulates innate immune responses in macrophages. *Blood*, 2011 May5;117(18):4796-804.
128. Schwartzenruber DJ, Lawson D, Richards J, Conry RM, **Miller DM**, Treisman J, Gailani F, Riley L, Conlon K, Bockaj B, Kendra K, White RL, Gonzalez R, Kuzel T, Curti B, Leming P, Whitman E, Balkisson J, Reintgen D, Kaufman H, Marincola F, Merino M, Choyke P, Vena D, Hwu P. A phase III multi-institutional randomized study of immunization with gp100:209-217(210M) peptide followed by high dose IL-2 vs. IL-2 alone in patients with metastatic melanoma. *N Engl J Med.*, 2011 June 2;364(22):2119-27.

129. Natarajan N, Telang S, **Miller D**, Chensey J. Novel immunotherapeutic agents and small molecule antagonists of signaling kinases for the treatment of metastatic melanoma. *Drugs*. 2011 Jul 9; 71(10):1233-50.
130. Deng Z, Cheng Z, Xiang X, Yan J, Zhuang X, Liu C, Jiang H, Ju S, Zhang L, Grizzle W, Mobley J, Roman J, **Miller D**, Zhang HG: Tumor Cell Cross Talk with Tumor-Associated Leukocytes Leads to Induction of tumor Exosomal Fibronectin and Promotes Tumor Progression. *Am J Pathol*. 2011 Nov 5. (Epub ahead of print)
131. Zhuang X, Xiang X, Grizzle W, Sun D, Zhang S, Axtell RC, Ju S, Mu J, Zhang L, Steinman L, **Miller D**, Zhang HG: Treatment of brain inflammatory diseases by delivering exosome encapsulated anti-inflammatory drugs from the nasal region to the brain. *Mol Ther*. 2011 Oct; 19(10):1769-79. doi: 10.1038/mt.2011.164. Epub 2011 Sep 13.
132. Xiang X, Zhuang X, Ju S, Zhang S, Jiang H, Mu J, Zhang L, **Miller D**, Grizzle W, Zhang HG: miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. *Oncogene*. 2011 Aug 4;30(31):3440-53. Epub 2011 Apr 4
133. Telang S, Rasku MA, Clem AL, Carter K, Klarer AC, Badger WR, Milam RA, Rai SN, Pan J, Gragg H, Clem BF, McMasters KM, **Miller DM**, Chesney J: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma. *BMC Cancer*. 2011 Dec 13; 11(1):515.
134. Sedoris KC, Thomas SD, Clarkson CR, Muench D, Islam A, Singh R, **Miller DM**: Genomic c-Myc Quadplex DNA Selectively Kills Leukemia. *Mol Cancer Ther*. 2012 Jan;11(1):66-76. [Epub 2011 Nov. 14]
135. **Miller DM**, Thomas SD, Sedoris K, Islam A, Muench D, Clarkson C, Koller, C: Using Human Observations to Gain Biologic Insights and New Testaments; Discovery a Quadruplex-forming DNA Aptamer as an Anticancer Agent in *The Primo Vascular System: Its Role in Cancer and Regeneration*. 2011 Springer Publishing
136. Deng Z, chng Z, Xiang X, Yan J, Zhuang X, Liu C, Jiang H, Ju S, Zhang L, Grizzle W, Mobley J, Roman J, **Miller D**, Zhang HG. Tumor cell cross talk with tumor-associated leukocytes leads to induction of tumor exosomal fibronectin and promotes tumor progression. *Am J Pathol*. 2012 Jan;180(1):390-8.
137. Ratajczak j, Kucia m, Mierzejewska k, Liu R, Kim CH, Natarajan N, Sharma V, **Miller DM**, Maciejewski J, Ratajczak MZ: A novel view of Paroxysmal Nocturnal Hemoglobinuria (PNH) pathogenesis: more motile PNH hematopoietic stem/progenitor cells (HSPCs) displace normal HSPCs from their niches in bone marrow due to defective adhesion, enhanced migration and mobilization in response to erythrocyte-released sphingosine-1 phosphate (S1P) gradient. *Leukemia*. 20 February 2012; doi: 10.1038/leu.2012.46
138. **Miller DM**, Thomas SD, Islam A, Muench D, Sedoris K.: c-Myc and Cancer Metabolism. *Clin Cancer Res*. 2012 Oct 15;18(20):5546-53. doi: 10.1158/1078-0432.CCR-12-0977.

139. Islam MA, Thomas SD, Slone S, Alatassi H, **Miller DM**: Tumor-associated primo vascular system is derived from xenograft, not host. *Exp Mol Pathol.* 2012 Sep 19. doi:pil: S0014-4800(12)00126-8. 10.1016/j.yexmp.2012.09.004.
140. Xiang X, Deng Z, Zhuang X, Ju S, Mu J, Jiang H, Zhang L, Yan J, **Miller D**, Zhang HG.: Grhl2 determines the epithelial phenotype of breast cancers and promotes tumor progression. *PLoS One.* 2012;7(12):e50781. doi: 10.1371/journal.pone.0050781. Epub 2012 Dec 17.
141. Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Wang Q, Hong J, Zhang L, Kronenberg M, Yan J, **Miller D**, Zhang HG.: Intestinal mucus-derived nanoparticles mediate activation of Wnt/ β -catenin signaling plays a role in induction of liver NKT cell anergy. *Hepatology.* 2012 Sep 18. doi: 10.1002/hep.26086. [Epub ahead of print]
142. Sun D, Zhuang X, Zhang S, Deng ZB, Grizzle W, **Miller D**, Zhang HG.: Exosomes are endogenous nanoparticles that can deliver biological information between cells. *Adv Drug Deliv Rev.* 2012 Jul 6. doi:pil: S0169-409X(12)00213-X. 10.1016/j.addr.2012.07.002. [Epub ahead of print]
143. Wang B, Zhuang X, Deng ZB, Jiang H, Mu J, Wang Q, Xiang X, Guo H, Zhang L, Dryden G, Yan J, **Miller D**, Zhang HG.: Targeted drug delivery to intestinal macrophages by bioactive nanovesicles released from grapefruit. *Mol Ther.* 2013 Aug 13. doi: 10.1038/mt.2013.190. [Epub ahead of print]
144. Ju S, Mu J, Dokland T, Zhuang X, Wang Q, Jiang H, Xiang X, Deng ZB, Wang B, Zhang L, Roth M, Welti R, Mobley J, Jun Y, **Miller D**, Zhang HG.: Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. *Mol Ther.* 2013 Jul;21(7):1345-57. doi: 10.1038/mt.2013.64. Epub 2013 Jun 11.
145. Deng ZB, Zhuang X, Ju S, Xiang X, Mu J, Liu Y, Jiang H, Zhang L, Mobley J, McClain C, Feng W, Grizzle W, Yan J, **Miller D**, Kronenberg M, Zhang HG.: Exosome-like nanoparticles from intestinal mucosal cells carry prostaglandin E2 and suppress activation of liver NKT cells. *J Immunol.* 2013 Apr 1;190(7):3579-89. doi: 10.4049/jimmunol.1203170. Epub 2013 Mar 6.
146. Wang Q, Zhuang X, Mu J, Deng ZB, Jiang H, Xiang X, Wang B, Yan J, **Miller D**, Zhang HG.: Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids. *Nat Commun.* 2013;4:1867. doi: 10.1038/ncomms2886.
147. Islam, A, Thomas, S, **Miller, DM**: Pu-27 G-quadruplex induces extensive DNA damage in both telomeric and non-telomeric regions of DNA. *J. Biol. Chem.* 2014 Mar 21;289(12):8521-31. doi: 10.1074/jbc.M113.505073. Epub 2014 Jan 24.
148. Clem BF, O'Neal J, Tapolsky G, Clem AL, Imbert-Fernandez Y, Kerr DA 2nd, Klarer AC, Redman R, **Miller DM**, Trent JO, Telang S, Chesney J.: Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer. *Mol Cancer Ther.* 2013 Aug;12(8):1461-70. doi: 10.1158/1535-7163.MCT-13-0097. Epub 2013 May 14.

149. Jiang H, Wang P, Wang Q, Wang B, Mu J, Zhuang X, Zhang L, Yan J, **Miller D**, Zhang HG.: Quantitatively Controlling Expression of miR-17~92 Determines Colon Tumor Progression in a Mouse Tumor Model. *Am J Pathol*. 2014 Mar 27. pii: S0002-9440(14)00149-7. doi: 10.1016/j.ajpath.2014.01.037. [Epub ahead of print]
150. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, Mu J, Zhang L, Wang B, Yan J, Miller D, Zhang HG.: Restoration of MiR-17/20a in Solid Tumor Cells Enhances the Natural Killer Cell Anti-tumor Activity by Targeting Mekk2. *Cancer Immunol Res*. 2014 May 6. [Epub ahead of print]
151. Mu J, Zhuang X, Wang Q, Jiang H, Deng ZB, Wang B, Zhang L, Kakar S, Jun Y, **Miller D**, Zhang HG. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. *Mol Nutr Food Res*. 2014 May 19. doi: 10.1002/mnfr.201300729. [Epub ahead of print]
152. Jiang H, Wang P, Li X, Wang Q, Deng ZB, Zhuang X, Mu J, Zhang L, Wang B, Yan J, **Miller D**, Zhang HG. Restoration of MiR-17/20a in Solid Tumor Cells Enhances the Natural Killer Cell Anti-tumor Activity by Targeting Mekk2. *Cancer Immunol Res*. 2014 May 6. [Epub ahead of print]
153. Jiang H, Wang P, Wang Q, Wang B, Mu J, Zhuang X, Zhang L, Yan J, **Miller D**, Zhang HG. Quantitatively Controlling Expression of miR-17~92 Determines Colon Tumor Progression in a Mouse Tumor Model. *Am J Pathol*. 2014 May;184(5):1355-68. doi: 10.1016/j.ajpath.2014.01.037. Epub 2014 Mar 27.
154. Kakar SS, Ratajczak MZ, Powell KS, Moghadamfalahi M, **Miller DM**, Batra SK, Singh SK.: Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells. *PLoS One*. 2014 Sep 29;9(9):e107596. doi: 1371/journal.pone.0107596.
155. Chaires, JB, Trent, JO, Gray, RD, Dean, WL, Busgaglia, R, Thomas, SD, **Miller, DM**: Common hTERT Promoter Mutations Cause Quadruplex DNA Instability and Constitutive Overexpression of hTERT *PLoS One*, in press.
156. Sellers K, Fox MP, Bousamra M, Slone SP, Higashi RM, **Miller DM**, Yan J, Wang Y, Lane AN, Fan TW: Pyruvate Carboxylase is the Critical Anaplerotic Enzyme in Early Stage Human Non-Small Cell Lung Cancer, *Journal of Clinical Investigation*, In Press.
157. Bousamra M, Fan TW, Higashi RM, Kloecker G, Lane AN, **Miller DM**. Clinical aspects of metabolomics. Submitted Book Chapter.